Cobalt's Altace Generic Gets FDA Approval, 180 Days Of Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
King and Cobalt appear to be in settlement talks over ongoing patent litigation in Boston federal court.
You may also be interested in...
King Signs Generic Altace Distribution Agreement With Cobalt
Patent infringement litigation between the two companies is ongoing.
King Signs Generic Altace Distribution Agreement With Cobalt
Patent infringement litigation between the two companies is ongoing.
Altace Patent Trial Set To Begin Feb. 13
King Therapeutics' defense against generic competition of ACE inhibitor Altace (ramipril) is scheduled to go to trial in Boston federal court Feb. 13, CEO Brian Markison said Feb. 7 during the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference